Loading
Gemcitabine / Pembrolizumab / Metastatic Triple Negative Breast Cancer · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a study registration for an active Phase 2 trial testing a four-drug combination (trilaciclib, pembrolizumab, gemcitabine, carboplatin) in metastatic triple-negative breast cancer. No efficacy or safety results have been posted in this registry record; the trial is still recruiting or recently closed to enrollment.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Metastatic Triple-Negative Breast Cancer; age from 18 Years. Intervention: Trilaciclib, Pembrolizumab, Gemcitabine, and Carboplatin. n = 36. 1 site: United States.
This is a study registration for an active Phase 2 trial testing a four-drug combination (trilaciclib, pembrolizumab, gemcitabine, carboplatin) in metastatic triple-negative breast cancer. No efficacy or safety results have been posted in this registry record; the trial is still recruiting or recently closed to enrollment.
This is a registry record only; no results, efficacy data, safety data, or outcome measures are reported.
The source did not state who this applies to in practice.
Phase 2 trial with estimated enrollment of 36 participants testing a four-drug combination; no results are reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06027268). This is a study registration, not published results. Lead sponsor: Wake Forest University Health Sciences. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 36 participants (ESTIMATED). Conditions: Metastatic Triple-Negative Breast Cancer. Interventions: DRUG: Trilaciclib; DRUG: Pembrolizumab; DRUG: Gemcitabine; DRUG: Carboplatin. Primary outcome measures: Objective Response , 6 months (initiation of protocol directed therapy until either a partial response is achieved or treatment discontinuation). Brief summary: The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: * to evaluate the anti-cancer efficacy (assess how well it works) * to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.